Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers

HIV Medicine

Volumn 10, Issue 3, 2009, Pages 157-162

  Palacios, Ricardo ^a   Senise, J F ^a   Vaz, M J R ^a   Diaz, R S ^a   Castelo, A ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antiretroviral agents; CD4T cell count; HIV 1; Vertical transmission

Indexed keywords

ANTIRETROVIRUS AGENT; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION CONTROL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MATERNAL CARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SHORT COURSE THERAPY; VERTICAL TRANSMISSION; VIRUS DETECTION; VIRUS LOAD; BLOOD; CD4 LYMPHOCYTE COUNT; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; RISK FACTOR; TRANSMISSION; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS; RNA, VIRAL; VIRAL LOAD;

EID: 61349195243     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00665.x     Document Type: Article

References (31)

1. Hawkins D, Blott M, Clayden P et al. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission of HIV. HIV Med 2005; 6 (Suppl. 2): 107-148.
2. Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. October 12, 2006: 65.
3. Ministério da Saúde do Brasil, Secretaria de Vigilância em Saúde. Recomendações para profilaxia da transmissão vertical do HIV e terapia anti-retroviral em gestantes. Brasília: Ministério da Saúde do Brasil, 2007.
4. El-Sadr WM, Lundgren JD, Neaton JD et al. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
5. Ministério da Saúde do Brasil, Secretaria de Vigilância em Saúde. Recomendações para terapia anti-retroviral em adultos infectados pelo HIV -2007/2008. Brasília: Ministério da Saúde do Brasil, 2007: 209.
6. Palacios R, Senise JF, Vaz MJR, Castelo A. Factores asociados a respuesta virológica en mujeres que usaron profilaxis antirretroviral de gran actividad para transmisión materno-fetal del Virus de la Inmunodeficiencia Humana tipo 1 (VIH-1). Enferm Infecc Microbiol Clin 2008; 26: 411-415.
7. Lyall EG, Blott M, de Ruiter A et al. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission. HIV Med 2001; 2: 314-334.
8. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States -24 January 2001, Vol. 2006.
9. Ministério da Saúde do Brasil, Coordenação Nacianal de DST e AIDS. Recomendações para terapia anti-retroviral em adultos e adolescentes infectados pelo HIV -2000. Brasília: Ministério de Saúde do Brasil, 2000: 31.
10. Colven R, Harrington RD, Spach DH, Cohen CJ, Hooton TM. Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection. Ann Intern Med 2000; 133: 430-434.
11. Kilby JM, Goepfert PA, Miller AP et al. Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report. Ann Intern Med 2000; 133: 435-438.
12. Worthington MG, Ross JJ. Aseptic meningitis and acute HIV syndrome after interruption of antiretroviral therapy: Implications for structured treatment interruptions. AIDS 2003; 17: 2145-2146.
13. Zeller V, Charlois C, Duvivier C, Bricaire F, Katlama C. Pseudo-primary infection syndrome following discontinuation of antiretroviral therapy. Antivir Ther 2001; 6: 191-193.
14. Daar ES, Bai J, Hausner MA, Majchrowicz M, Tamaddon M, Giorgi JV. Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion. Ann Intern Med 1998; 128: 827-829.
15. Knysz B, Gasiorowski J, Czarnecki M, Gladysz A. Viral rebound syndrome in two HIV-1-positive patients after structured treatment interruption. Viral Immunol 2005; 18: 579-581.
16. Orbea RL, Dominguez CA, Justo AE. Síndrome mononucleósico con patrones viro-inmunológicos similares a los de una primoinfección VIH-1 tras interrupción del tratamiento antirretroviral eficaz. An Med Interna 2002; 19: 321-322.
17. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: A controlled, prospective trial. AIDS 2004; 18: 439-446.
18. Tarwater PM, Parish M, Gallant JE. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clin Infect Dis 2003; 37: 1541-1548.
19. Boschi A, Tinelli C, Ortolani P, Moscatelli G, Morigi G, Arlotti M. CD4 cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy. AIDS 2004; 18: 2381-2389.
20. Skiest DJ, Morrow P, Allen B et al. It is safe to stop antiretroviral therapy in patients with preantiretroviral CD4 cell counts >250 cells/ μL. J Acquir Immune Defic Syndr 2004; 37: 1351-1357.
21. Pai N, Tulsky J, Lawrence J, Colford J Jr, Reingold A. Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults. Cochrane Database Syst Rev 2005; 4: CD005482.
22. Montaner J, Harris M, Hogg R. Structured treatment interruptions: A risky business. Clin Infect Dis 2005; 40: 601-603.
23. Thiebaut R, Pellegrin I, Chene G et al. Immunological markers after long-term treatment interruption in chronically HIV-1-infected patients with CD4 cell count above 400 × 10(6) cells/L. AIDS 2005; 19: 53-61.
24. Mussini C, Bedini A, Borghi V et al. CD4 cell-monitored treatment interruption in patients with a CD4 cell count >500 × 106cells/ L. AIDS 2005; 19: 287-294.
25. Toulson AR, Harrigan R, Heath K et al. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200cells/mm 3. J Infect Dis 2005; 192: 1787-1793.
26. Martin F, Navaratne L, Khan W et al. Pregnant women with HIV infection can expect healthy survival: Three-year follow-up. J Acquir Immune Defic Syndr 2006; 43: 186-192.
27. Phillips AN, Dunn D, Sabin C et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005; 19: 487-494.
28. Vaz MJ, Barros SM, Palacios R et al. HIV-infected pregnant women have greater adherence with antiretroviral drugs than non-pregnant women. Int J STD AIDS 2007; 18: 28-32.
29. Wood E, Hogg RS, Harrigan PR, Montaner JS. When to initiate antiretroviral therapy in HIV-1-infected adults: A review for clinicians and patients. Lancet Infect Dis 2005; 5: 407-414.
30. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. MMWR Recomm Rep 1998; 47: 43-82.
31. Ananworanich J, Siangphoe U, Hill A et al. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: The HIV Netherlands Australia Thailand Research Collaboration 001.4 Study. J Acquir Immune Defic Syndr 2005; 39: 523-529.